Paper - WANFANG MED ONLINE

You Position: Home > Paper

Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease

( views:23, downloads:12 )

Author:: No author available

Journal Title:: Chinese Medical Journal

Issue:: 14

DOI:: 10.4103/0366-6999.185857

Key Word:: Chronic Obstructive Pulmonary Disease;Osteoporosis;Osteoprotegerin;Receptor Activator of Nuclear Factor-κB Ligand;Tumor Necrosis Factor Receptors;Tumor Necrosis Factor-alpha

Abstract： Background:Osteoporosis is a common complication of chronic obstructive pulmonary disease (COPD).Recent clinical and biological researches have increasingly delineated the biomolecular pathways of bone metabolism regulation in COPD.We extended this work by examining the specific association and potential contribution of the osteoprotegerin (OPG)/receptor activator of nuclear factor-κB ligand (RANKL) axis to the pathogenesis of osteoporosis in advanced COPD.The aim of this study was to assess the relationships of serum OPG,RANKL,and tumor necrosis factor-alpha (TNF-α) with bone turnover in men with very severe COPD.Methods:Pulmonary function,T-score at the lumbar spine (LS) and femoral neck (FN),serum OPG,RANKL,soluble receptor of tumor necrosis factor-alpha-Ⅰ and Ⅱ (sTNFR-Ⅰ,sTNFR-Ⅱ),osteocalcin (OC),and β-CrossLaps (βCL) levels were measured in 45 men with very severe stage COPD and 36 male non-COPD volunteers.COPD patients and healthy controls were compared using an independent t-test and Mann-Whitney U-test.The Pearson coefficient was used to assess the relationships between variables.Results:OPG and OC were lower in male COPD patients than in control subjects whereas RANKL,serum βCL,TNF-α,and its receptors were higher.OPG directly correlated with forced expiratory volume in 1 s (FEV1) ％ predicted (r =0.46,P ＜ 0.005),OC (r =0.34,P ＜ 0.05),LS (r =0.56,P ＜ 0.001),and FN T-score (r =0.47,P ＜ 0.01).In contrast,serum RANKL inversely associated with LS and FN T-score (r =-0.62,P ＜ 0.001 and r =-0.48,P ＜ 0.001) but directly correlated with βCL (r =0.48,P ＜ 0.001).In addition,OPG was inversely correlated with RANKL (r =-0.39,P ＜ 0.01),TNF-α (r =-0.56,P ＜ 0.001),and sTNFR-Ⅰ (r =-0.40,P ＜ 0.01).Conclusion:Our results suggest that serum OPG and RANKL levels are inversely associated with bone loss in men with advanced stage COPD.

Reference

[1]Hai-Xia Zhou,Xue-mei OU,Yong-Jiang Tang,etc.Advanced Chronic Obstructive Pulmonary Disease: Innovative and Integrated Management Approaches[J].2015,(21).
[2]Qing-Sheng Yu,Wan-Shou Guo,Li-Ming Cheng,etc.Glucocorticoids Significantly Influence the Transcriptome of Bone Microvascular Endothelial Cells of Human Femoral Head[J].2015,(14).
[3]Yang Lin,Hai Yong,ZHOU Jun-lin.Osteoprotegerin and osteoprotegerin ligand expression during human marrow stromal cell differentiation and their effect on osteoclast formation[J].2011,(13).
[4]DAI Yi,SHEN Lin.Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women[J].2007,(22).
[5]Rui-Ying Wang,HU Liu,Li-Juan Ma,etc.Comparison of Serum Adiponectin in Smoke-induced Pulmonary Emphysema Rats Fed Different Diets[J].2016,(2).
[6]Zorica, Ciric,Ivana, Stankovic,Tatjana, Pejcic,etc.Osteoporosis in patients with chronic obstructive pulmonary disease.[J].2012,66(6).
[7]Feng,Y.,Liang,B..The association of low bone mineral density with systemic inflammation in clinically stable COPD[J].2012,42(1).
[8]Bucay N.,Sarosi I.,Dunstan C. R.,etc.Osteoprotegerin-Deficient Mice Develop Early Onset Osteoporosis and Arterial\u00a0calcification[J].1998.
[9]E A, Kochetkova,M V, Volkova,T N, Surovenko,etc.[Cytokine status in patients with chronic obstructive pulmonary diseases and its relationship with bone tissue functional state].[J].2004,76.
[10]Eastell R,Saleh G,Rogers A,etc.Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women.[J].2002,87(10).
[11]Gourgoulianis,K.I.,Fountoulis,G.A.,Minas,M.,etc.Association of Bone Mineral Density, Parameters of Bone Turnover, and Body Composition in Patients With Chronic Obstructive Pulmonary Disease[J].2012,15(2).
[12]James M Duckers,Bronwen AJ Evans,William D Fraser,etc.Low bone mineral density in men with chronic obstructive pulmonary disease[J].2011,12(1).
[13]Sheryl F, Vondracek,Norbert F, Voelkel,Michael T, McDermott,etc.The relationship between adipokines, body composition, and bone density in men with chronic obstructive pulmonary disease.[J].2009,4.
[14]Patel S,Huang Y,Sterrett A,etc.The recognition and treatment of vertebral fractures in males with chronic obstructive pulmonary disease.[J].2008,102(8).
[15]Jyothi, Hattiholi,Gajanan S, Gaude.Prevalence and correlates of osteoporosis in chronic obstructive pulmonary disease patients in India.[J].2014,31(3).
[16]Spruit MA,van den Borne B,Graat Verboom L.Correlates of osteoporosis in chronic obstructive pulmonary disease: An underestimated systemic component.[J].2009,103(8).
[17]Bhattacharyya, Parthasarathi,Paul, Rantu,Ghosh, Malabika,etc.Prevalence of osteoporosis and osteopenia in advanced chronic obstructive pulmonary disease patients.[J].2011,28(3).
[18]Nuti R,Siviero P,Maggi S.Vertebral fractures in patients with chronic obstructive pulmonary disease: the EOLO Study.[J].2009,20(6).
[19]Peng Bai,Yongchang Sun,Jianmin Jin,etc.Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis[J].2011,12(1).
[20]Browner WS,Lui LY,Cummings SR.Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.[J].2001,86(2).
[21]Oliver Tschopp,Annette Boehler,Rudolf Speich,etc.Osteoporosis Before Lung Transplantation: Association with Low Body Mass Index, but Not with Underlying Disease[J].2002,2(2).
[22]Eagan TM,Ueland T,Wagner P.Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study.[J].2010,35(3).
[23]Carpenter PC,Bailey WC,Wise RA,etc.Loss of bone density with inhaled triamcinolone in Lung Health Study II.[J].2004,170(12).
[24]Riccobene S,Celotta G,Signorelli SS,etc.Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels.[J].2004,15(5).
[25]Boe J,Forli L,Mellbye OJ,etc.Cytokines, bone turnover markers and weight change in candidates for lung transplantation.[J].2008,21(1).
[26]Stone MD,Edwards PH,Shale DJ,etc.Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease.[J].2004,170(12).
[27]Dougall WC,Chaisson M.The RANK/RANKL/OPG triad in cancer-induced bone diseases.[J].2006,25(4).
[28]Garcia DF,de Dios Luna J,de la Higuera M,etc.The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.[J].2005,16(11).
[29]Pavol Pobeha,Darina Petrasova,Ruzena Tkacova,etc.Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD.[J].2014,108(4).
[30]E M, Dennison,D K, Dhanwal,S O, Shaheen,etc.Is lung function associated with bone mineral density? Results from the Hertfordshire Cohort Study.[J].2013,8.
[31]Duplomba, L,Heymann, D,Baud'huin, M,etc.RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases[J].2007,64(18).
[32]Barnes PJ,Celli BR.Systemic manifestations and comorbidities of COPD.[J].2009,33(5).
[33]Regan,E.A.,Radcliff,T.A.,Hutt,E.,etc.Improving hip fractures outcomes for COPD patients[J].2013,10(1).
[34]Watanabe, Reiko,Tanaka, Takeshi,Aita, Keisuke,etc.Osteoporosis is highly prevalent in Japanese males with chronic obstructive pulmonary disease and is associated with deteriorated pulmonary function[J].2015,33(4).
[35]Sattler AM,Hofbauer LC,Schoppet M,etc.Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease.[J].2004,74(1).
[36]Maisch B,Hofbauer LC,Sattler AM,etc.Increased osteoprotegerin serum levels in men with coronary artery disease.[J].2003,88(3).
[37]Vega D,Maalouf NM,Sakhaee K.CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.[J].2007,92(12).
[38]Zhang,P.-F.,Pan,L.,Luo,Z.-Y.,etc.Interrelationship of Circulating Matrix Metalloproteinase-9, TNF-α, and OPG/RANK/RANKL Systems in COPD Patients with Osteoporosis[J].2013,10(6).
[39]Ferguson GT,Calverley PM,Anderson J.Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study.[J].2009,136(6).
[40]Szalay F,Dunkel K,Bajnok E,etc.High serum osteoprotegerin and low RANKL in primary biliary cirrhosis.[J].2003,38(4).
[41]Jingqiu Lu,Jianhua Xu,Yu Wang,etc.Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis.[J].2012,32(11).